+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Interstitial Lung Disease - Pipeline Insight, 2021

  • ID: 5237632
  • Drug Pipelines
  • January 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • AdAlta
  • aTyr Pharma
  • Bristol-Myers Squibb
This “Interstitial Lung Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Interstitial Lung Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Interstitial Lung Disease Understanding

Interstitial Lung Disease: Overview

Interstitial lung disease (ILD) is another term for pulmonary fibrosis, which means “scarring” and “inflammation” of the interstitium (the tissue that surrounds the lung's air sacs, blood vessels and airways). This scarring makes the lung tissue stiff, which can make breathing difficult. ILD may be limited to the lung, or it can be related to a condition that may affect other parts of the body, such as rheumatoid arthritis or sarcoidosis.

Symptoms

Most people with ILD have symptoms that make breathing difficult, including:
  • Shortness of breath
  • Coughing,
  • Decreased exercise tolerance
  • Fatigue
  • Weight loss
Diagnosis

People with interstitial lung disease usually go to the doctor because of shortness of breath or a cough. The doctor will probably use imaging tests of your lungs to find out the problem. Such tests include- Chest X-ray, Lung function test, CT scan, and lung biopsy.

Treatment

The treatment you get depends on the type of ILD you have and its cause. Antibiotics are used to treat most interstitial pneumonias. Corticosteroids are used for some forms of interstitial lung disease, inflammation in your lungs causes damage and scarring.

Interstitial Lung Disease Emerging Drugs Chapters

This segment of the Interstitial Lung Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interstitial Lung Disease Emerging Drugs

AD-214: AdAlta

AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. At the back end of AD-214 is the Fc Fragment or tail region of a traditional monoclonal antibody that will extend the half-life or duration of time in which the i-body will stay in the body. Currently, in phase 1 of clinical trials for indication interstitial lung disease.

Abatacept: Bristol-Myers Squibb

Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. Currently, in phase 2 of clinical trials for indication interstitial lung disease.

ATYR1923: aTyr Pharma

ATYR1923 is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. ATYR1923 works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. ATYR1923 is conducting a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that cause progressive fibrosis of the lung

Interstitial Lung Disease: Therapeutic Assessment

This segment of the report provides insights about the different Interstitial Lung Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Interstitial Lung Disease

There are approx. 5+ key companies which are developing the therapies for Interstitial Lung Disease. The companies which have their Interstitial Lung Disease drug candidates in the mid to advanced stage, i. e. phase III and Phase II include, AdAlta and others.

Phases

This report covers around 10+ products under different phases of clinical development like
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interstitial Lung Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interstitial Lung Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interstitial Lung Disease drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Interstitial Lung Disease R&D. The therapies under development are focused on novel approaches to treat/improve Interstitial Lung Disease.
Interstitial Lung Disease Report Insights
  • Interstitial Lung Disease Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Interstitial Lung Disease Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Interstitial Lung Disease drugs?
  • How many Interstitial Lung Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interstitial Lung Disease?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Interstitial Lung Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Interstitial Lung Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • AdAlta
  • Bristol-Myers Squibb
  • aTyr Pharma
Key Products
  • AD-214
  • Abatacept
  • ATYR1923

This report will be delivered within 1-3 business days
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AdAlta
  • aTyr Pharma
  • Bristol-Myers Squibb
Introduction

Executive Summary

Interstitial Lung Disease: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Interstitial Lung Disease - Analytical Perspective

In-depth Commercial Assessment
  • Interstitial Lung Disease companies’ collaborations, Licensing, Acquisition - Deal Value Trends
Interstitial Lung Disease Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Interstitial Lung Disease Key Companies

Interstitial Lung Disease Key Products

Interstitial Lung Disease- Unmet Needs

Interstitial Lung Disease- Market Drivers and Barriers

Interstitial Lung Disease- Future Perspectives and Conclusion

Interstitial Lung Disease Analyst Views

Interstitial Lung Disease Key Companies

Appendix

List of Tables
Table 1 Total Products for Interstitial Lung Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Interstitial Lung Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • AdAlta
  • Bristol-Myers Squibb
  • aTyr Pharma
Note: Product cover images may vary from those shown
Adroll
adroll